Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZA197 (AZA-197)是一种选择性 Cdc42抑制剂。在临床前小鼠异种移植模型中,它通过下调 PAK1活性来抑制原发性结肠癌的生长并延长生存期。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 2,300 | 现货 | ||
5 mg | ¥ 5,570 | 现货 | ||
10 mg | ¥ 7,790 | 现货 | ||
25 mg | ¥ 11,500 | 现货 | ||
50 mg | ¥ 15,600 | 现货 | ||
100 mg | ¥ 20,800 | 现货 |
产品描述 | AZA197 (AZA-197) is a selective Cdc42 inhibitor. It acts by inhibiting primary colon cancer growth and prolonging survival in a preclinical mouse xenograft model by downregulation of PAK1 activity. |
体外活性 | In SW620 and HT-29 human colon cancer cells, AZA197(1, 2, 5 and 10 μM; 24 h) demonstrated selectivity for Cdc42 without inhibition of Rac1 or RhoA GTPases from the same family. AZA197 suppressed colon cancer cell proliferation, cell migration and invasion and increased apoptosis associated with down-regulation of the PAK1 and ERK signaling pathways in vitro[1]. |
体内活性 | Systemic AZA197(i.p. injections with 100 μg) treatment reduced tumor growth in vivo and significantly increased mouse survival in SW620 tumor xenografts. Ki-67 staining and tissue TUNEL assays showed that both inhibition of cell proliferation and induction of apoptosis associated with reduced PAK/ERK activation contributed to the AZA197-induced therapeutic effects in vivo[1]. |
别名 | AZA 197, AZA-197 |
分子量 | 408.58 |
分子式 | C24H36N6 |
CAS No. | 1249398-09-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Slightly soluble
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AZA197 1249398-09-1 Cell Cycle/Checkpoint CDK AZA 197 AZA-197 Inhibitor inhibitor inhibit